Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 701.85 USD -0.9% Market Closed
Market Cap: 77.1B USD
Have any thoughts about
Regeneron Pharmaceuticals Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one REGN stock under the Base Case scenario is 611.33 USD. Compared to the current market price of 701.85 USD, Regeneron Pharmaceuticals Inc is Overvalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REGN Relative Value
Base Case
611.33 USD
Overvaluation 13%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.6
P/S
P/S
Price to Sales
5.6
vs History
66
vs Industry
49
Median 3Y
6.5
Median 5Y
6.4
Industry
7.6
Forward
5.3
More Details
16.6
P/E
P/E
Price to Earnings
16.6
vs History
58
vs Industry
6
Median 3Y
19.2
Median 5Y
18.4
Industry
22.1
Forward
15.3
More Details
18.2
P/OCF
P/OCF
Price to OCF
18.2
vs History
55
vs Industry
7
Median 3Y
17
Median 5Y
19.5
Industry
21.9
More Details
23.3
P/FCFE
P/FCFE
Price to FCFE
23.3
vs History
49
vs Industry
6
Median 3Y
24.9
Median 5Y
23.4
Industry
23.4
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
98
vs Industry
21
Median 3Y
3.7
Median 5Y
3.9
Industry
2.5
More Details
5.1
EV/S
EV/S
Enterprise Value to Sales
5.1
vs History
71
vs Industry
42
Median 3Y
6
Median 5Y
5.9
Industry
7.5
Forward
4.9
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
71
vs Industry
39
Median 3Y
6.9
Median 5Y
6.8
Industry
9.3
More Details
15.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.1
vs History
49
vs Industry
5
Median 3Y
15.1
Median 5Y
15.1
Industry
4.2
Forward
12.5
More Details
16.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.7
vs History
47
vs Industry
4
Median 3Y
16.8
Median 5Y
16.8
Industry
4
Forward
13.2
More Details
16.5
EV/OCF
EV/OCF
Enterprise Value to OCF
16.5
vs History
53
vs Industry
7
Median 3Y
15.7
Median 5Y
17.8
Industry
5.9
More Details
21.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.1
vs History
61
vs Industry
5
Median 3Y
21.9
Median 5Y
23.5
Industry
3.9
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
98
vs Industry
32
Median 3Y
3.8
Median 5Y
3.8
Industry
4.5
More Details

Multiples Across Competitors

REGN Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
133.7B AUD 5.7 31.7 19.6 24.5
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4 -136.2 -110 -80.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.6B USD 15.1 -95.2 -226 -158.8
P/S Multiple
Revenue Growth P/S to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/S: 3 457 241.3
5.6
23%
0.2
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.4
220%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.1
96%
0.2
P/E Multiple
Earnings Growth P/E to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/E: 211.6
16.6
44%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.7
65%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBITDA: 16.2
15.1
35%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
42%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -226 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBIT: 21.2
16.7
42%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.5
54%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -158.8 N/A N/A

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.